Marksans Pharma Limited has informed the Exchange regarding a press release dated Jun 30, 2025, titled "Receipt of EIR from USFDA for inspection conducted at manufacturing facility of Company s subsidiary Time-Cap Laboratories, Inc.".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly owned US subsidiary, Time-Cap Laboratories Inc., has received the Establishment Inspection Report (EIR) from the USFDA for its manufacturing facility in Farmingdale, New York. This follows a cGMP inspection conducted at the facility between April 16 and April 24, 2025. Receiving the EIR typically indicates that the USFDA has completed its review and classified the inspection outcome, generally meaning no further regulatory action is expected from this inspection. The facility is a key part of Marksans Pharma's US manufacturing and supply operations for generic formulations.
This is a positive regulatory update for shareholders, as closure of the USFDA inspection without escalation reduces compliance uncertainty for Marksans' US operations. It supports uninterrupted production and supplies from the Time-Cap facility, which is important for the company's US generic formulations business.